Clinical Outcomes, Based on Initial Risk Stratification, a Median of 2.5 Years After Initial Ablation Using Suppressed Thyroglobulin of Less Than 1 ng/mL and Stimulated Thyroglobulin of Less Than 2 ng/mL to Define NCED
| Parameter | NCED | Clinical recurrence | Persistent disease | TB uptake only | P |
|---|---|---|---|---|---|
| Excluding distant metastases at diagnosis (M1) | |||||
| THW (n = 69) | 73% (50) | 6% (4) | 17% (12) | 4% (3) | NS |
| rhTSH (n = 302) | 82% (246) | 4% (12) | 11% (32) | 4% (12) | |
| Total (n = 394) | 80% (296) | 4% (16) | 12% (44) | 4% (15) | |
| AJCC6 I and II without distant metastases | |||||
| THW (n = 49) | 78% (38) | 2% (1) | 16% (8) | 4% (2) | NS |
| rhTSH (n = 195) | 84% (163) | 2% (4) | 11% (22) | 3% (6) | |
| Total (n = 244) | 82% (201) | 2% (5) | 12% (30) | 3% (8) |
TB = thyroid bed; NS = not statistically significant.